Evidence map›Paper›PMID 36641673›Full record

ArticleJournal of Alzheimer's disease : JAD2023

Insomnia Symptoms and Biomarkers of Alzheimer's Disease in the Community.

Jessica Nicolazzo, Marina Cavuoto, Ella Rowsthorn, Lachlan Cribb, Lisa Bransby, Madeline Gibson, Prudence Wall, Dennis Velakoulis, Dhamidhu Eratne, Rachel Buckley and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Midlife sleep characteristics and Alzheimer's disease biomarkers 20 years later.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Jessica NicolazzoThe Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.
Marina CavuotoThe Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.
Ella RowsthornThe Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.
Lachlan CribbThe Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.
Lisa BransbyThe Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.
Madeline GibsonThe Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.
Prudence WallThe Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.
Dennis VelakoulisNeuropsychiatry at The Royal Melbourne Hospital, Parkville, VIC, Australia.
Dhamidhu EratneNeuropsychiatry at The Royal Melbourne Hospital, Parkville, VIC, Australia.
Rachel BuckleyMelbourne School of Psychological Sciences, University of Melbourne, Parkville, VIC, Australia.
Nawaf YassiDepartment of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.
Stephanie YiallourouThe Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.
Amy BrodtmannThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia.
Garun S HamiltonMonash Lung, Sleep, Allergy and Immunology, Monash Health, Clayton, VIC, Australia.
Matthew T NaughtonDepartment of Respiratory Medicine, Alfred Health and Monash University, Melbourne, VIC, Australia.
Yen Ying LimThe Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.
Matthew P PaseThe Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC, Australia.
Monash University · AUUniversity of Melbourne · AUEastern Health · AUHarvard University · USMassachusetts General Hospital · USThe Royal Melbourne Hospital · AU

Funding

Contributions of sleep to preclinical and clinical Alzheimer's diseaseR01AG062531 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HIMALI, JAYANDRA JUNG, PASE, MATTHEW · 2020 to 2023
$3.1M
Sex differences in the progression of Alzheimer's disease: is menopause the key?R00AG061238 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BUCKLEY, RACHEL FRANCES · 2021 to 2023
$747k
Elucidating the mechanisms underlying sex differences in cognitive decline due to preclinical Alzheimer's diseaseK99AG061238 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BUCKLEY, RACHEL FRANCES · 2019 to 2020
$273k
NIA NIH HHS K99 AG061238NIA NIH HHS R00 AG061238NIA NIH HHS R01 AG062531
6 · The paper itself

Abstract

backgroundInsomnia is one of the most common sleep disorders yet its relationship to the biology of Alzheimer's disease remains equivocal.

objectiveWe investigated the cross-sectional relationship between insomnia symptom severity and cerebrospinal fluid (CSF) concentrations of Alzheimer's disease biomarkers in a cognitively unimpaired middle-aged community sample.

methodsA total of 63 participants from the Healthy Brain Project (age = 59±7 years; 67% women) completed a lumbar puncture and two weeks of actigraphy to measure two of insomnia's core features: difficulty initiating sleep (prolonged sleep onset latency) and difficulty maintaining sleep (wake after sleep onset [WASO] and number of awakenings). Additionally, the Insomnia Severity Index (ISI) was completed by 58 participants. Linear and Tobit regression were used to estimate the associations between each insomnia variable and CSF Aβ42, phosphorylated tau 181 (p-tau181), total-tau, and neurofilament light chain protein (NfL), adjusting for age, sex, and APOEɛ4 genotype.

resultsHigher ISI score was associated with greater average levels of CSF Aβ42 (per point: 30.7 pg/mL, 95% CI: 4.17-57.3, p = 0.023), as was higher WASO (per 10 min: 136 pg/mL, 95% CI: 48-223, p = 0.002) and more awakenings (per 5:123 pg/mL, 95% CI = 55-192, p < 0.001). Difficulty initiating sleep was not associated with CSF Aβ42, nor were insomnia features associated with p-tau181, total-tau, or NfL levels.

conclusionInsomnia symptoms were associated with higher CSF Aβ42 levels in this relatively young, cognitively unimpaired sample. These findings may reflect increased amyloid production due to acute sleep disruption.

Indexed as

Alzheimer DiseaseSleep Initiation and Maintenance DisordersAgedAmyloid beta-PeptidesBiomarkersFemaleHumansMaleMiddle AgedPeptide Fragmentstau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAlzheimer’s diseaseamyloiddementiainsomniasleep

Identifiers

PMID36641673
PMCPMC11446570
OpenAlexW4314447460

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.